 NEWTOWN, Pa., Sept. 28, 2021 GLOBE NEWSWIRE -- Onconova Therapeutics, Inc. NASDAQ: ONTX Onconova, a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the closing of its previously announced underwritten public offering. A total of 5,000,000 shares of its common stock were sold at a public offering price of 4.20 per share. The gross proceeds of the offering to the Company are 21 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, Onconova granted the underwriters a thirty-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions. 